Despite that adapter CAR T cell technologies will have to prove their superiority over blinatumomab in resistant CD19+ leukemias and lymphomas, they have a very promising prospect as adapter CAR technologies have the chance to overcome the unspecific BiTE toxicities beyond CD19 targeting. This evidence concerns the gene CD19 and lymphoma.